



## Broadview Ventures Announces Promotions of Thomas Needham and Daniel Gottlieb to Managing Directors

**BOSTON – September 26, 2025** – Broadview Ventures, a mission-driven investment firm dedicated to accelerating the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke, is pleased to announce the promotions of Thomas Needham and Daniel Gottlieb to Managing Directors of Broadview Ventures. Tom will be responsible for Broadview's investment strategy and portfolio management in addition to his current roles as Head of the Biopharmaceuticals practice and Managing Director of Longview Ventures. Daniel will lead Broadview's MedTech practice and will be responsible for Broadview's business management and operations. Tom and Daniel's promotions will occur on January 1, 2026 as Chris Colecchi, Broadview's founding Managing Director, begins to step back from his full-time responsibilities after leading Broadview for 18 years.

"I am thrilled that Tom and Daniel have agreed to take on the roles of Managing Director, to lead Broadview into the future," said Chris Colecchi. "Their combined industry, venture investing and operating experience – along with their strength of character and long history at Broadview – make them ideal choices to lead Broadview. This succession plan reflects my complete confidence in Tom and Daniel's leadership and capabilities and I look forward to continuing to work with them in support of Broadview's mission."

Tom has over 30 years of experience in venture capital investing, business development and C-suite executive management in public and private biotechnology companies. Tom joined Broadview in 2018 as a Director and Head of BioPharma and has shared responsibility for all aspects of Broadview's investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement. Tom has closed 17 transactions across Broadview and Longview, including nine new Broadview investments. Seven are new companies spun out of leading academic medical centers raising their first investor capital at time of Broadview's investment.

Tom was instrumental in the original setup and structuring of the Longview Ventures investment strategy in 2018 and has played a leadership role in the successful portfolio build to 13 total investments, resulting in his recent promotion to Managing Director, Longview Ventures. Tom currently serves on the boards of IsomAb and Basking Biosciences, including serving as Basking's Chairman (2020 thru 2023). He also serves as board observer at Comanche Bio, HAYA Therapeutics, Mosanna Therapeutics and Alveron Pharma. Previously, Tom represented Broadview on the

board at Antag Therapeutics, Renovacor (NYSE:RCOR, acquired by Rocket Pharma), including serving as Renovacor's Chairman (2019 thru 2021), and held board observer roles at NIDO Surgical (acquired) and Cardero Therapeutics (now Epirium Bio).

Daniel has over 25 years of experience in the cardiovascular medtech space, including corporate venture capital, corporate business development, and operational roles in public and private device companies, including positions at Guidant and Abbott Vascular. Daniel joined Broadview in 2019 and was promoted to a Director of the MedTech practice in 2024. He has shared responsibility for all aspects of Broadview's investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement, and has also taken on an increased leadership role in Broadview's management and operations. Daniel has closed nine transactions across Broadview and Longview, including four investments involving academic spinouts. Daniel currently serves on the boards of XII Medical, Cardiosense, Alleviant, and CroiValve, and holds board observer roles at Nyra Medical and CorFlow Therapeutics. Previously, Daniel held board observer roles at Nido Surgical (acquired) and Puzzle Medical, and as a member of Guidant Compass at CardioMEMS (acquired by St. Jude) and Neovasc (NASDAQ:NVCN). Outside of Broadview, Daniel serves as a member of the AdvaMed Board Investor Advisory Committee, the Selection Committee of the Cleveland Clinic's Phase 1 Technology Validation and Start-up Fund, and the External Advisory Committee of the DRIVEN Accelerator Hub.

### **About Broadview Ventures**

Broadview Ventures is a mission-driven investment organization that makes targeted investments in early-stage companies to accelerate the development of innovative therapeutics, devices, and diagnostics for cardiovascular disease and stroke. Broadview is funded by the Leducq Charitable Trust.

To learn more about Broadview's portfolio and activities, please visit our [website](#).

Broadview Ventures | 265 Franklin Street | Boston, MA 02110 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!